

Optimizing Patient Outcomes in Bipolar Disorder: Long-term Management of Major Depressive Episodes
Tweetorial #3 References

Tweet 4

Citrome L, Tocco M, Zeni C, Pikalov A, Goldman R. Assessing the benefit-risk ratio of approved treatments for bipolar depression using likelihood to be helped or harmed (LHH) analyses. *CNS Spectr*. 2021;26(2):146. doi:10.1017/S109285292000231X

Tweet 6

Escudero MAG, Gutiérrez-Rojas L, Lahera G. Second generation antipsychotics monotherapy as maintenance treatment for bipolar disorder: a systematic review of long-term studies. *Psychiatr Q*. 2020;91(4):1047-1060. doi:10.1007/s11126-020-09753-2

Tweet 7

Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression: a major unsolved challenge. *Int J Bipolar Disord*. 2020;8(1):1. Published 2020 Jan 6. doi:10.1186/s40345-019-0160-1

Tweet 9

Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression: a major unsolved challenge. *Int J Bipolar Disord*. 2020;8(1):1. Published 2020 Jan 6. doi:10.1186/s40345-019-0160-1

Bobo WV. *Mayo Clin Proc*. 2017;92(10):1532-1551. doi:10.1016/j.mayocp.2017.06.022

Goodwin GM, Haddad PM, Ferrier IN, et al. *J Psychopharmacol*. 2016;30(6):495-553. doi:10.1177/0269881116636545

Grunze H, Vieta E, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. *World J Biol Psychiatry*. 2018;19(1):2-58. doi:10.1080/15622975.2017.1384850

National Collaborating Centre for Mental Health. Bipolar disorder. Updated March 2020. <https://www.nice.org.uk/guidance/cg185/evidence/full-guideline-pdf-4840895629>.

Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord*. 2018;20(2):97-170. doi:10.1111/bdi.12609

Tweet 10

Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry*. 2014;171(2):160-168. doi:10.1176/appi.ajp.2013.13070984

Tweet 11

Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry*. 2014;171(2):160-168.
doi:10.1176/appi.ajp.2013.13070984

Tweet 13

Lydiard RB, Culppepper L, Schiöler H, Gustafsson U, Paulsson B. Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies. *Prim Care Companion J Clin Psychiatry*. 2009;11(5):215-225.
doi:10.4088/PCC.08m00659

Tweet 14

Lydiard RB, Culppepper L, Schiöler H, Gustafsson U, Paulsson B. Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies. *Prim Care Companion J Clin Psychiatry*. 2009;11(5):215-225.
doi:10.4088/PCC.08m00659

Tweet 15

McIntyre RS, Suppes T, Earley W, Patel M, Stahl SM. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: Post hoc analysis of 3 randomized, placebo-controlled studies. *CNS Spectr*. 2019;25(4):1-9. doi:10.1017/S1092852919001287

Tweet 16

Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. *J Clin Psychiatry*. 2015;76(3):284-292. doi:10.4088/JCP.14m09081

Tweet 17

Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. *J Clin Psychiatry*. 2015;76(3):284-292. doi:10.4088/JCP.14m09081

Tweet 18

Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. *Arch Gen Psychiatry*. 2003;60(11):1079–1088.
doi:10.1001/archpsyc.60.11.1079

Tweet 19

Silva MT, Zimmermann IR, Galvao TF, Pereira MG. Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis. *J Affect Disord*. 2013;146(3):310-318.
doi:10.1016/j.jad.2012.11.001

Glossary

AE, adverse event
Ben, benefit
CGI-BP, Clinical Global Impressions-Bipolar Scale
CGI-S, Clinical Global Impressions-Severity Scale
Dif, difference
ES, effect size
Esp, especially
FDA, US Food and Drug Administration
IR, immediate release
LHH, likelihood to be helped or harmed
LOCF, last observation carried forward
LS, least squares
MADRS, Montgomery-Asberg Depression Rating Scale
mg/d, milligrams per day
MMRM, mixed effects model for repeated measures
NNH, number needed to harm
OFC, olanzapine/fluoxetine combination
PBO, placebo
Pts, patients
Q, quality
RCTs, randomized, controlled trials
RR, relative risk
SAE, serious adverse event
SE, secondary endpoint
SGA, second-generation antipsychotic
SSRI, selective serotonin reuptake inhibitor
TEAE, treatment-emergent adverse event
Tx, treatment
Wk, week
XR, extended release
YMRS, Young Mania Rating Scale